Navigation Links
Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
Date:9/7/2011

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present the latest data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16. Study results evaluating the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, as well as the investigational sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor, empagliflozin (BI-10773), will be featured among the seven presentations. Linagliptin 5 mg is marketed under the trade name Tradjenta™ (linagliptin) tablets in the U.S. and was approved by the U.S. Food and Drug Administration (FDA) in May 2011 to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

A long-term study evaluating the efficacy and safety of linagliptin in patients with type 2 diabetes was selected by EASD as an oral presentation, taking place on Friday, September 16.

The presentations are as follows: Linagliptin DataTitleFormat AuthorsDate/TimePreclinicalDPP-4 Inhibition - A New Approach for the Treatment of Uraemic Cardiomyopathy

Poster

824-P

L Chaykovska, K von Websky, S Heiden, J Rahnenfuhrer, T Klein, B Hocher

Date: Tues, Sept. 13

Time: 12:30−1:30 p.m.Phase III (52-week)Long-term Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes and Severe Renal Impairment

Poster

821-P

J Newman, J McGill, S Patel, C Friedrich, C Sauce, H-J Woerle

Date: Tues, Sept. 13

Time: 12:30−1:30 p.m.Phase III (pooled analysis)Linagliptin Improves
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... HILL, N.C. , March 27, 2015 ... is essential to meeting challenges in clinical development, market ... face tighter regulations, the Medical Affairs function is expected ... by mature markets. According to research ... study participants have a group dedicated to Medical Affairs. ...
(Date:3/27/2015)... 2015 Object recognition technology has a unique ... elderly. The VelaSense ® mobile platform ... independent, productive and fulfilling lives. VelaSense ® will ... to identify objects from a one million object database, ... object databases for personal use. Visus ...
(Date:3/27/2015)... AUGUSTA, Ga. , March 27, 2015  Holographic ... innovator in the field of holographic medical imaging, is ... of its Kickstarter campaign. Launching on April 20 th ... Voxbox and Voxbox Pro. The 8-inch and 22-inch displays ... at home for the first time. In addition to ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... to Company Oncology Programs to be Presented, SOUTH ... Incorporated announced,today that four posters containing non-clinical data ... the American Association,for Cancer Research (AACR) to be ... CA. These posters are related to multiple oncology,programs ...
... 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and Adolor ... and,provided an update on the clinical development ... 3, double blind, placebo-controlled (12,month) study, was ... of alvimopan 0.5 mg twice daily in ...
Cached Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
(Date:3/28/2015)... MILAN (PRWEB) March 28, 2015 ... thought-leaders in the fields of osteoporosis, osteoarthritis and ... on Osteoporosis, it may be the first time ... educational research forum that the hot-button topic is ... Based on the well-accepted scientific principles of Wolff’s ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... surgery experiences re-injury, according to research presented today at ... ) Specialty Day. The study examined the long term ... younger. , “We examined survey data from 242 ... noted lead author Justin P. Roe, MBBS, FRACS, from ...
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... 24 Many religions teach that selflessly "doing unto ... , , A growing body of ... promoting health and general well-being--research that will be outlined more fully ... Research Says." (1) , , ...
... fertility solutions,agencies today announced the launch of a unique cooperative ... donors dropping out before the,retrieval process is completed. , ... is an initiative by The Center for Egg,Options (CEO), Northbrook, ... Egg donation is an ...
... institution , ... Washington, DC (Vocus) November 24, 2008 ... , dedicated new research facilities today, increasing the space of one ... square feet. , , , , ,Elected officials and scientific leaders ...
... For over a decade Ochsner Health System,has enjoyed ... in improved patient care, cost savings and increased revenues ... of New Orleans have,seen more than their share of ... have left the greater New Orleans hospital infrastructure,badly damaged. ...
... its January 1,2009 opening, San Francisco Village-Northside (SFV-N) announces ... (IOA). , SFV-N ... older adults and those who care for them live ... they wish or are,able. A model that is sweeping ...
... think of the holidays,as a time for joy and togetherness. ... emotionally trying time. The buildup of the,pressure to create the ... negative consequences, such as depression,anxiety and substance dependency. , ... ) , "During the ...
Cached Medicine News:Health News:Conferees to Explore How Religious Practice Reaps Health 2Health News:Conferees to Explore How Religious Practice Reaps Health 3Health News:Three Chicago Area Fertility Agencies Launch 'Shared Risk' Program 2Health News:Children's National Dedicates New Research Facility 2Health News:Children's National Dedicates New Research Facility 3Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 2Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 3Health News:Institute on Aging Collaborates With New Program San Francisco Village 2Health News:Under Wraps: Uncovering the Secrets and Lies of the Holiday Season 2
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... The S8 Elite is the premium CPAP device ... generators. The S8 line of flow generators are ... first flow generators to include an option of ... to the device for simplicity and convenience. Premium ...
Medicine Products: